Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children
M Knuf, G Leroux-Roels, H Rümke… - Human vaccines & …, 2015 - Taylor & Francis
Mass immunization of children has the potential to decrease infection rates and prevent the
transmission of influenza. We evaluated the immunogenicity, safety, and tolerability of …
transmission of influenza. We evaluated the immunogenicity, safety, and tolerability of …
A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups
B Michiels, F Govaerts, R Remmen, E Vermeire… - Vaccine, 2011 - Elsevier
PURPOSE: To systematically review the evidence regarding the efficacy, effectiveness and
risks of the use of inactivated influenza vaccines in children, healthy adults, elderly …
risks of the use of inactivated influenza vaccines in children, healthy adults, elderly …
Point-of-use mixing of influenza H5N1 vaccine and MF59 adjuvant for pandemic vaccination preparedness: antibody responses and safety. A phase 1 clinical trial
MJ Mulligan, DI Bernstein, S Frey… - Open forum …, 2014 - academic.oup.com
Abstract Background. Avian influenza A/H5N1 has threatened human health for nearly 2
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
decades. Avian influenza A vaccine without adjuvant is poorly immunogenic. A flexible rapid …
Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district
C Cristiani, M Tuccori, P Pepe, A Sarteschi, F Maddalo… - Vaccine, 2011 - Elsevier
BACKGROUND: The occurrence of pandemic H1N1 influenza in 2009 led health authorities
to promptly start massive vaccination campaigns. Due to the need of shortening time for …
to promptly start massive vaccination campaigns. Due to the need of shortening time for …
MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza …
V Baldo, T Baldovin, A Floreani, AM Carraro, R Trivello… - Vaccine, 2007 - Elsevier
The immunogenicity and reactogenicity of two influenza vaccines were evaluated in a
randomised, double-blind trial in north-east Italy during winter 2005–2006. Of 238 adult …
randomised, double-blind trial in north-east Italy during winter 2005–2006. Of 238 adult …
MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines
TF Tsai - Yakugaku Zasshi, 2011 - jstage.jst.go.jp
MF59-adjuvanted seasonal trivalent inactivated (ATIV) vaccine licensed since 1997 and
MF59-adjuvanted pandemic H1N1 vaccines have been distributed to approximately 80M …
MF59-adjuvanted pandemic H1N1 vaccines have been distributed to approximately 80M …
Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly
Background: The higher effectiveness of MF59®-adjuvanted trivalent influenza vaccine
(MF59-TIV) vs. nonadjuvanted TIV in preventing influenza-related hospitalizations was …
(MF59-TIV) vs. nonadjuvanted TIV in preventing influenza-related hospitalizations was …
Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis
WEP Beyer, JJP Nauta, AM Palache, KM Giezeman… - Vaccine, 2011 - Elsevier
Several inactivated influenza vaccine formulations for systemic administration in man are
currently available for annual (seasonal) immunization: split virus and subunit (either plain …
currently available for annual (seasonal) immunization: split virus and subunit (either plain …
Effectiveness of A (H1N1) pdm09 influenza vaccine in adults recommended for annual influenza vaccination
G Gefenaite, M Tacken, J Bos, I Stirbu-Wagner… - Plos one, 2013 - journals.plos.org
Introduction Because of variability in published A (H1N1) pdm09 influenza vaccine
effectiveness estimates, we conducted a study in the adults belonging to the risk groups to …
effectiveness estimates, we conducted a study in the adults belonging to the risk groups to …
[PDF][PDF] Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine–preliminary report
Trial of Influenza A (H1N1) 2009 Monovalent MF59-Adjuvanted Vaccine — Preliminary
Report Page 1 The new england journal of medicine 10.1056/nejmoa0907650 nejm.org 1 …
Report Page 1 The new england journal of medicine 10.1056/nejmoa0907650 nejm.org 1 …